Ocumension Therapeutics has announced that its product, OT-703 (ILUVIEN®), has been approved for a real-world study in the Boao Lecheng International Medical Tourism Pilot Zone in Hainan Province, China. OT-703 is an injectable, non-biodegradable fluocinolone acetate intravitreal implant designed for the treatment of diabetic macular edema $(DME.AU)$. The implant provides a continuous microdose of corticosteroid fluocinolone acetonide in the eye for up to 36 months. It is the only FDA-approved corticosteroid intraocular implant with a three-year sustained-release period, and it has recently received regulatory approval in Hong Kong. Ocumension holds exclusive rights for its development and commercialization in Greater China, South Korea, and parts of Southeast Asia, following a licensing agreement with Alimera Sciences, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.